Get the Stockscreener App
1.7295
3.92%
-0.0705
Rein Therapeutics Inc stock is traded at $1.7295, with a volume of 7,053.
It is down -3.92% in the last 24 hours and up +1.74% over the past month.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
See More
Previous Close:
$1.80
Open:
$1.8
24h Volume:
7,053
Relative Volume:
0.19
Market Cap:
$39.43M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-2.84%
1M Performance:
+1.74%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.7295
$1.803
1-Week Range:
$1.529
$1.82
52-Week Range:
$1.35
$3.50
Rein Therapeutics Inc Stock (RNTX) Company Profile
Name
Rein Therapeutics Inc
Sector
Industry
Phone
(737) 802-1989
Address
12407 N. MOPAC EXPY., AUSTIN
Compare RNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
1.7295 | 39.43M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.03 | 129.44B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.52 | 61.42B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
615.11 | 38.44B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.81 | 33.29B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
241.75 | 26.95B | 3.81B | -644.79M | -669.77M | -6.24 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-24-17 | Initiated | BofA/Merrill | Buy |
| Jul-24-17 | Initiated | Jefferies | Buy |
| Jul-24-17 | Initiated | William Blair | Outperform |
Rein Therapeutics Inc Stock (RNTX) Latest News
Rein Therapeutics to integrate Qureight’s platform in trial of IPF treatment - Yahoo Finance
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF - PR Newswire
Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025 - Citizen Tribune
Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference - The Victoria Advocate
Breakthrough Lung Regeneration Study: Rein Therapeutics to Present New IPF Treatment Data at ATS 2025 - Stock Titan
Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases - The Malaysian Reserve
Rein Therapeutics (RNTX) Secures Two Key Patents for Innovative Lung Treatment | RNTX Stock News - GuruFocus
Rein Therapeutics Granted Two Patents Covering The Novel Formulation And Administration Methods Of Dry Powder LTI-03 For Treatment Of Respiratory Diseases - marketscreener.com
Antibiotics Might Increase Risk of Childhood Asthma, Allergies - WFMZ.com
Muscle Quality Could Be Key To Successful Hip Replacement - WFMZ.com
Early Menopause Might Mean Greater Age-Related Brain Decline - WFMZ.com
Microplastics Could Be Contributing To Clogged Arteries - WFMZ.com
Psilocybin Use Dramatically Increasing In U.S. - WFMZ.com
Tesla Board Gets an Earful From State Treasurers Over Musk’s Focus - Yahoo Finance
Rein Therapeutics Announces a Publication in Biomedicines on the - GuruFocus
Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F - MarketScreener
Rein Therapeutics (RNTX) Showcases Promising Peptide for Lung Fi - GuruFocus
Cancer-fighting implant shows promise in treating tumors - WFMZ.com
ITC Makes Affirmative Preliminary Determination in Trade Cases on Chassis from Mexico, Thailand, and Vietnam, Wiley Rein LLP Reports - Yahoo Finance
Equities Analysts Offer Predictions for RNTX Q1 Earnings - Defense World
Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Malaysian Reserve
Will the tariffs lead to a recession? Here's how to know if we're in one - WFMZ.com
Rein Therapeutics, Inc. SEC 10-K Report - TradingView
Health Secretary Says Some Cuts to CDC Will Be Reversed - WFMZ.com
RFK Jr. Touts Vaccine While At Funeral of Texas Girl Who Died of Measles - WFMZ.com
Lawmakers may test Trump on tariffs this week as fears of a GOP election 'decimation' grow - Yahoo Finance
Some Folks Hit With Fees for Using Health Care Message Portals - WFMZ.com
RNTX stock touches 52-week low at $1.6 amid market challenges - Investing.com Canada
RNTX stock touches 52-week low at $1.6 amid market challenges By Investing.com - Investing.com South Africa
Trump says things are 'going very well' after worst stock market drop in years over tariffs - WFMZ.com
Aileron Therapeutics, Inc. Announces New Appointments - MarketScreener
Rein Therapeutics Delays Annual Report Filing - TipRanks
A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial - Frontiers
NCLA Asks Sixth Circuit to Rein in FINRA’s Unlawful Prosecution Regime - Yahoo Finance
Modi Banks on Households to Rein In a $346 Billion Debt Pile - Yahoo Finance
Crude oil drives higher with focus on geopolitical risks, OPEC+ plan to rein in production - Seeking Alpha
Oil prices rise for second consecutive week on expected tighter supply - Yahoo Finance
Congo Considers Asking Indonesia to Help Rein In Cobalt Supply - Yahoo Finance
USAID reinstates contracts for Georgia company that helps feed malnourished kids after Elon Musk responds to CNN reporting - AOL
Reeves Pledges to Rein In UK Borrowing as Welfare Backlash Grows - Yahoo Finance
Daybreak West March 11: Ag chair seeks to rein in CARB costs - Agri-Pulse
OpinionThrough ‘radical transparency,’ Kennedy can finally rein in Big Pharma - AOL
Trump's Plan To Rein In Regulators Could Erode Market Trust, Says $2.3 Trillion Asset Manager - Yahoo Finance
Saratoga Springs event celebrates Belmont countdown while supporting therapeutic horses - WRGB
Carney Vows to Rein In Government Spending, Cap Public Service in Canada - Yahoo Finance
British biotech rebrands as Octavian, seeking to establish new empire after setbacks in 2024 - Fierce Pharma
Should You Invest in Wolfspeed Inc (WOLF) Now? - The News Heater
Esco Technologies, Inc (ESE) Shares Up Despite Recent Market Volatility - The News Heater
PDD Holdings Inc ADR (PDD) Shares Rise Despite Market Challenges - The News Heater
Palantir Technologies Inc (PLTR) Stock: A Closer Look at the Analyst Ratings - The News Heater
Rein Therapeutics (RNTX) Income Statement & Balance Sheet 2025 - MarketBeat
Rein Therapeutics Inc Stock (RNTX) Financials Data
There is no financial data for Rein Therapeutics Inc (RNTX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
5.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):